In a transaction that will create a diversified, high-growth specialty pharmaceutical company, Mallinckrodt plc and Questcor Pharmaceuticals, Inc. have announced a definitive merger agreement under whichMallinckrodt will acquire Questcorin a cash and stock transaction valuedat approximately $5.6 billion, as detailed in the press release below issued by the companies. The transaction is subject to customary closing conditions and is currently expected to be completed in the third calendar quarter of 2014. Latham & Watkins represents Quincy Questcor Pharmaceuticals in the transaction with a corporate team consisting of partners Cary Hyden, Scott Shean, Paul Tosetti and Michael Treska, with associates John Raney, Jeff Holgate, Aneta Ferguson and Brett Urig (all are based in the firm’s Orange County, CA office except for Mr. Tosetti, who is based in Los Angeles). Advice has also been provided on tax matters by partners Laurence Stein in Los Angeles and Nicholas DeNovio in Washington, D.C., with associate Eric Song in Los Angeles; on finance matters by partner Wesley Holmes, with associates Benjamin Cohen, Ryan deFord and Joseph Skrokov, in New York; on benefits and compensation matters by partner Jim Barrall and associate Michelle Carpenter in Los Angeles; on compliance matters by partners Peter Wald in San Francisco and Michele Johnson in Orange County, with associate Andrew Gray in Orange County; on antitrust matters by partner Michael Egge in Washington, D.C./Brussels, with counsel Hector Armengod in Brussels and associate Patrick English in Washington, D.C., on environmental matters by partner Christopher Norton and associate Charles Anthony in Orange County; and on intellectual property matters by counsel David Kuiper in Orange County. For further information, please contact Cary Hyden at 1.714.755.8254.